Design, molecular docking, synthesis, and in vitro pharmacological evaluation of biomolecules-histone deacetylase inhibitors conjugates with carbohydrazide as a novel zinc-binding group
Alwash, A., Naser, N., Zalzala, M. (2022). Design, molecular docking, synthesis, and in vitro pharmacological evaluation of biomolecules-histone deacetylase inhibitors conjugates with carbohydrazide as a novel zinc-binding group. EKB Journal Management System, 65(10), 83-99. doi: 10.21608/ejchem.2022.104511.4830
Ameer Hussein Alwash; Noor Hatef Naser; Munaf Hashim Zalzala. "Design, molecular docking, synthesis, and in vitro pharmacological evaluation of biomolecules-histone deacetylase inhibitors conjugates with carbohydrazide as a novel zinc-binding group". EKB Journal Management System, 65, 10, 2022, 83-99. doi: 10.21608/ejchem.2022.104511.4830
Alwash, A., Naser, N., Zalzala, M. (2022). 'Design, molecular docking, synthesis, and in vitro pharmacological evaluation of biomolecules-histone deacetylase inhibitors conjugates with carbohydrazide as a novel zinc-binding group', EKB Journal Management System, 65(10), pp. 83-99. doi: 10.21608/ejchem.2022.104511.4830
Alwash, A., Naser, N., Zalzala, M. Design, molecular docking, synthesis, and in vitro pharmacological evaluation of biomolecules-histone deacetylase inhibitors conjugates with carbohydrazide as a novel zinc-binding group. EKB Journal Management System, 2022; 65(10): 83-99. doi: 10.21608/ejchem.2022.104511.4830

Design, molecular docking, synthesis, and in vitro pharmacological evaluation of biomolecules-histone deacetylase inhibitors conjugates with carbohydrazide as a novel zinc-binding group

Egyptian Journal of Chemistry
Article 8, Volume 65, Issue 10, October 2022, Page 83-99  XML PDF (1.31 MB)
Document Type: Original Article
DOI: 10.21608/ejchem.2022.104511.4830
View on SCiNiTO View on SCiNiTO
Authors
Ameer Hussein Alwash email orcid 1; Noor Hatef Naserorcid 2; Munaf Hashim Zalzala3
1Department of pharmaceutical chemistry, college of pharmacy, Albayan University, Baghdad, Iraq
2Pharmaceutical chemistry department, Faculty of Pharmacy, Kufa University, Najaf, Iraq
3Department of pharmacology and toxicology, College of Pharmacy, University of Baghdad, Iraq
Abstract
Histone deacetylase inhibitors (HDACIs) are newly emerging chemotherapeutic agents which have shown great potential in the treatment of many types of cancers. However, these agents have many drawbacks which may limit their clinical application such as low oral bioavailability, and low intracellular concentration in solid tumors which may require high doses leading to side and maybe toxic effects. Additionally, their zinc-binding group (ZBG) is partly responsible partly for their poor physicochemical properties. In silico design, synthesis, and characterization of new HDACIs involving biomolecules (biotin and phenylalanine) with carbohydrazide as a novel ZBG were achieved successfully and hopefully, to increase the targetability and to overcome the limitations of traditional hydroxamate-based HDACIs. MTT assay of compounds 2c and 3d (which are biotin and phenylalanine-linked derivatives respectively) showed higher antiproliferative activity than SAHA and 5-FU against MCF7 and lower cytotoxic effect against NHF cell lines which were consistent with the docking study results. Additionally, compound 1b displayed comparable cytotoxic results to SAHA against MCF7 and NHF. These results were found to be encouraging for the involvement of biomolecules in the future development of HDACIs. Therefore, carbohydrazide as a ZBG could be thought of as a counterpart to hydroxamate moiety and may be considered as a successful replacement for hydroxamate moiety upon designing new HDACIs.
Keywords
Keywords: Histone deacetylase inhibitors; Zinc-binding group; cancer-targeting; phenylalanine; biotin
Statistics
Article View: 513
PDF Download: 219